Do I need to report expected side effects like dissociation or mild nausea?

No. Expected pharmacological effects at therapeutic doses, such as dissociation, mild nausea, or a brief rise in blood pressure, are not adverse events and do not require formal reporting, though you should still mention them at your next check-in.

Will reporting an adverse event affect my access to future ketamine treatment?

Reporting itself should not automatically end your treatment. Your provider may adjust your dose, add monitoring, or pause treatment temporarily depending on what happened, but withholding information from your provider makes it harder for them to keep you safe.

What if I don't have my medication's lot number?

Check the label on the medication packaging or the shipping materials first. If you can't find it, your compounding pharmacy can look it up using your name and the date your prescription was filled.

Can I report an adverse event to the FDA without giving my name?

Yes. FDA MedWatch accepts reports directly from patients, and you can choose not to include identifying information, though providing contact details helps the FDA follow up if it needs more information.

Reporting Adverse Events in Telehealth Ketamine

Editorial review

Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.

Reporting adverse events in telehealth ketamine therapy means knowing three things before you start treatment: which symptoms are simply expected effects of the medication, which require you to contact your provider promptly, and which require an immediate call to 911. Patients who begin at-home ketamine without this preparation often hesitate when something unexpected happens, and that hesitation delays care and weakens the safety data that shapes how this treatment is practiced going forward.

This guide covers who to contact for non-emergency concerns, what information your provider or pharmacy will need, and the formal channels, including the FDA's MedWatch program, that exist for reporting problems beyond your own care team.

Quick Answer

Call 911 first for any life-threatening symptom, such as loss of consciousness, seizure, severe difficulty breathing, or chest pain, then notify your provider afterward. For non-emergency concerns like severe nausea, unusual perceptual disturbances, or new physical symptoms, contact your provider through their secure messaging system, email, or urgent phone line, ideally the same day. Have your session date, dose, symptom description, and medication lot number ready before you call. You can also file a report with FDA MedWatch, or contact your state pharmacy board or medical board if the event involves medication quality or provider care.

Types of Adverse Events in Telehealth Ketamine

Before you report anything, it helps to know which symptoms are a normal part of the ketamine experience and which count as an adverse event.

Expected Pharmacological Effects (Not Adverse Events)

These effects are typical of ketamine at therapeutic doses. They do not need to be reported as adverse events, though you may want to note them for your own records and for your next check-in with your provider:

Dissociation and altered perception
Mild elevation in blood pressure and heart rate
Mild nausea
Dizziness or lightheadedness
Cognitive impairment during and immediately after the session

Symptoms That Warrant Same-Day Provider Notification

Nausea or vomiting that was severe or interfered significantly with the session

Blood pressure readings substantially above your established thresholds

Psychological distress that was intense, prolonged, or frightening

Unusual visual or auditory disturbances that persist after the session

Mood changes, depersonalization, or confusion that emerge after the session

New urinary urgency, pain, or discomfort after starting ketamine

Any symptom that worries you, even if it isn't on this list

Call 911 First for These Symptoms

Loss of consciousness or unresponsiveness, a seizure, severe difficulty breathing, chest or arm pain, a severe headache suggesting a cardiac or vascular emergency, active self-harm behavior, or signs of a severe allergic reaction such as throat swelling, difficulty breathing, or hives covering large areas of the body all require an immediate call to 911. Notify your provider after emergency services are involved, not before. If you are having thoughts of self-harm, the SAMHSA National Helpline (1-800-662-4357) is also available for immediate support.

Who to Contact for Non-Emergency Adverse Events

Your Telehealth Provider's Direct Line

Your provider should give you a direct communication channel for adverse event reports between scheduled appointments. This is typically a secure messaging system inside the platform, a direct email address for your care team, or a phone number for non-emergency clinical questions. Confirm which channel your platform uses for urgent but non-emergency concerns, and test it before you need it, rather than during a session when you may not feel well enough to search for contact information.

Pharmacy Contact

If the adverse event may be related to the medication itself, such as an unusual color, texture, or smell, unexpected potency, or a concern about the compounded preparation, contact your compounding pharmacy directly. The pharmacy's number should be printed on your medication label. If you have concerns about medication quality, keep any remaining medication from the shipment rather than discarding it. The pharmacy may ask for it to be returned for analysis. If you are unsure whether your dose or symptoms fall within a typical range, our guide on ketamine and esketamine dose equivalence explains how sublingual and intranasal doses compare.

Compare your options

Move from the guide into a side-by-side comparison when you are ready to evaluate tradeoffs.

Compare options

Information to Have Ready When You Report

Your name, date of birth, and patient ID or account number

A description of what happened, in your own words

The date and time of the event relative to your session

How long the symptoms lasted

The date and time of the session and the dose you took

Whether you used alcohol, drugs, or supplements in the 24 hours before the session

Your pre-session blood pressure and heart rate readings

Any adjunct medications you took, such as anti-nausea medication

Whether your symptoms have resolved and whether you sought emergency care

The lot number from your medication packaging and your pharmacy's contact information

Formal Adverse Event Reporting Channels

Beyond your care team, several formal channels exist for reporting problems with ketamine treatment.

FDA MedWatch

The FDA MedWatch program collects reports of adverse events associated with medications, including compounded medications like sublingual ketamine troches. You or your provider can submit a report online or by calling 1-800-332-1088. A single adverse event report may not change practice on its own, but patterns visible only through aggregate reporting can identify safety signals that lead to protective action for future patients.

State Pharmacy Board

If your adverse event appears to involve medication quality, such as unexpected potency, contamination, or abnormal appearance, report it to your state pharmacy board in addition to your provider and the FDA. State pharmacy boards regulate compounding pharmacies and have investigatory authority over them.

Your State's Medical Board

If you believe an adverse event resulted from provider negligence, such as inadequate screening, failure to follow up on red flags, or inappropriate prescribing, you can file a complaint with your state medical board. Prescribing rules and oversight vary significantly by state; our state regulations guide explains what oversight looks like where you live.

Why Adverse Event Reporting Matters

The telehealth ketamine industry operates with less regulatory oversight than the standard FDA drug approval process, since ketamine troches are typically compounded rather than FDA-approved for this specific use. The U.S. Department of Health and Human Services publishes general telehealth regulatory guidance, but oversight of compounded medications used in telehealth settings sits primarily with state pharmacy boards and the FDA's compounding rules. Our overview of the federal investigation into online ketamine sellers covers how regulators are responding to gaps in oversight of this market. Until clinical trial data catches up, the real-world safety profile of at-home ketamine will be shaped largely by the quality of adverse event reporting from patients and providers. Reporting is not only in your own interest. It helps your provider protect you, contributes to the platform's safety protocols, may protect future patients from the same event, and adds to the evidence base that will inform future regulatory decisions about this treatment.

A Note on Underreporting

Adverse event underreporting is a well-documented problem across medical settings, and at-home ketamine treatment is no exception. Contributing factors include patients not recognizing that something was an adverse event rather than an expected effect, not knowing who to contact, worrying that reporting will jeopardize continued access to treatment, or simply forgetting to mention a minor event at the next check-in. Your provider cannot address what they do not know about. Reporting, even for events that seem minor, supports better care for you and for the patients who come after you.